Comparative Pharmacology
Head-to-head clinical analysis: FACTREL versus VANTAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTREL versus VANTAS.
FACTREL vs VANTAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist; stimulates pituitary release of LH and FSH initially, then suppresses gonadotropin secretion after chronic administration due to receptor downregulation.
Gonadotropin-releasing hormone (GnRH) agonist; continuous stimulation suppresses pituitary gonadotropin secretion, resulting in decreased testosterone production.
100 mcg subcutaneously or 100 mcg intravenously, single dose for pituitary stimulation testing.
10 mg subcutaneously every 24 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 30-45 minutes. Short half-life necessitates continuous or repeated administration for sustained therapeutic effect.
Terminal elimination half-life approximately 4 weeks (28 days) due to continuous release from the implant; after implant removal, plasma concentrations decline with a half-life of about 3-4 days.
Primarily renal (95% as unchanged drug and metabolites). Fecal excretion accounts for <5%.
Renal: negligible. Fecal: ~100% (unchanged drug). Histrelin is not metabolized and is excreted unchanged in feces via biliary elimination.
Category C
Category C
GnRH Agonist
GnRH Agonist